Contemporary management of patients with native mitral regurgitation in heart valve centres - 08/05/26
, Andrea Scotti b, c, Yohann Bohbot d, e, Julien Dreyfus f, Anne Bernard g, h, Yoan Lavie Badie i, Natacha Rousse a, Arnaud Sudre a, Christophe Tribouilloy d, e, Marcel Peltier d, e, Sebastian Ludwig b, j, Bertrand Marcheix i, Damien Eyharts i, Matthieu Steinecker f, Mohammed Nejjari f, Marie Luciani g, Christophe Saint Etienne g, Julien Ternacle k, l, Guillaume Bonnet b, k, Guillaume L’Official m, Elena Galli m, Patrizio Lancellotti n, o, Juan Granada b, Erwan Donal m, Thomas Modine kGraphical abstract |
Highlights |
• | Patients with mitral regurgitation (MR) were assessed at a heart valve centre (HVC). |
• | Eligibility for mitral valve (MV) intervention was associated with lower 2-year mortality. |
• | HVCs are pivotal to and propose an individualized ‘precision medicine’ approach. |
• | Future studies should assess whether HVCs improves outcomes of patients with severe MR. |
Abstract |
Background |
Despite a key role in the latest guidelines, the screening process of patients with mitral regurgitation (MR) referred to Heart Valve Centres (HVCs) remains unexplored.
Aims |
To investigate characteristics, management and outcomes of patients with native MR referred to HVCs.
Methods |
Between January 2017 and May 2021, all patients with MR referred to seven French HVCs for medico-surgical evaluation were included. Individual management was left to the local interdisciplinary HVC. Patients eligible to mitral valve (MV) intervention were compared with those deemed ineligible and left on medical therapy. The primary endpoint was 2-year all-cause mortality.
Results |
After exclusion for treatment refusal or non-MV surgery, a total of 823 patients were analysed: 662 eligible versus 161 ineligible to MV intervention. Among the 662 eligible patients, 382 (57.7%) underwent transcatheter edge-to-edge repair, 215 (32.5%) MV surgery, 40 (6.0%) transcatheter MV replacement and 25 (3.8%) were either on the waiting list at the end of follow-up ( n = 12) or had died before intervention ( n = 13). Ineligible patients had higher surgical risk scores (median EuroSCORE II 4.2% vs. 3.3%; P = 0.003; median Society of Thoracic Surgeons mortality risk score 4.3% vs. 3.5%; P = 0.023) and more advanced left ventricular (LV) impairment (mean LV ejection fraction 49.7% vs. 56.6%; P < 0.001). At 2 years, all-cause mortality was significantly higher in ineligible versus eligible patients (36.3% vs. 18.0%; P < 0.0001). After multivariable adjustment, HVC-defined eligibility for MV intervention was associated with lower 2-year mortality (hazard ratio: 0.54, 95% confidence interval: 0.35–0.84; P = 0.006).
Conclusion |
HVC interdisciplinary evaluation of severe native MR results in MV intervention in most cases. Eligibility for MV intervention was associated with lower risk of 2-year mortality.
Le texte complet de cet article est disponible en PDF.Keywords : Mitral regurgitation, Heart valve centre, Heart team, Transcatheter edge-to-edge repair, Transcatheter mitral valve replacement
Plan
Vol 119 - N° 5
P. 333-340 - mai 2026 Retour au numéro
Article précédent
- Transcatheter aortic valve implantation-related vascular access complications: Are balloon-expandable stent grafts a good option?
- Gabriel Saiydoun, Romain Gallet, Saadé Saadé, Madjid Boukantar, Camille Brasselet, Paul-Mathieu Chiaroni, Costin Radu, Nicolas Lellouche, Ziyad Gunga, Thierry Folliguet, Emmanuel Teiger
- Associated diseases and diuretic dosage to predict mortality in transthyretin amyloid cardiomyopathy
- Vincent Algalarrondo, Olivier Lairez, Marion Narbeburu, Pauline Fournier, Jerome Costa, Francoise Pelcot, Agnes Farrugia, Isabelle Durand-Zaleski, Herve Lilliu, Mathilde Bartoli, Stephane Fievez, Jeremie Rudant, Agathe Coste, Charlotte Noirot Cosson, Pierre Alexandre Squara, Giorgia Canali, Bertrand de Neuville, Michel S. Slama, Philippe Charron, Thibaud Damy
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?